Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company uses its cell-targeted lipid nanoparticle (ctLNP) platform and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoid innate immune sensors that have long prevented DNA from use in non-viral systems.

Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

COM:GENERATIONBIO

Generation Bio Co.

0.41

−5.33%

0.03

Last Close

0.37

02/04 20:00

Market Cap

27.14M

Beta: -

Volume Today

365.60K

Avg: -

name

homepage url

country

crunchbase url

employee count

sector

industry

revenue

raised capital

Description

competitor of

Metrics